Physician profile
Amber Allen
NPI 1871914259
$546.80
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.66 · 2020: $35.16 · 2021: $330 · 2022: $92.79.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $358.76 | 2019-2022 | |
| Misonix INC | $53.39 | 2021 | |
| Organogenesis INC. | $38.21 | 2020-2021 | |
| Kci USA, INC. | $26.11 | 2021 | |
| Biofrontera INC. | $24.14 | 2019 | |
| Mayne Pharma Commercial LLC | $23.93 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.26 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amber Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.